No Data
No Data
Cinda Biotech will announce multiple clinical data at the American Society of Clinical Oncology (ASCO) 2024 Conference
SAN FRANCISCO, USA, April 25, 2024/PRNewswire/ -- Cinda Biopharmaceutical Group (HKEx stock code: 01801), a biopharmaceutical company dedicated to the development, production and sale of innovative drugs for major diseases such as oncology, autoimmunity, metabolism, cardiovascular, ophthalmology, etc., announced today that it will release about 20 new clinical research data at the 2024 American Society of Clinical Oncology (ASCO) annual meeting, including the company's series of monoclonal antibodies, double antibodies and antibody-conjugated drugs (ADC) in the research pipeline, and Dabber Shudley (Cindy) monoclonal antibody injection), Nellick
Changes in Hong Kong stocks | Cinda Biotech (01801) rose more than 6%, demand for weight loss products surged, and the company's product, Maxidopeptide, has submitted a listing application for weight loss indications
Cinda Biotech (01801) rose more than 6%. As of press release, it rose 6.22% to HK$38.4, with a turnover of HK$299 million.
Direct change | Cinda Biotech rose more than 5% in the afternoon, and the cholangiocarcinoma treatment dabertan was approved for marketing in Macau, China
Cinda Biotech (01801) rose more than 5% in the afternoon. As of press release, it was up 5.15% to HK$35.7, with a turnover of HK$131 million.
More contests are coming! Global Data: 13 new weight loss drugs are expected to be launched by 2029
Pharmacists are preparing to launch around 13 new weight loss treatments in the US within the next five years due to a surge in demand for weight loss products, according to a new report from global data analysis and consulting firm Global Data.
Express News | Cinda Biotech: Dabertan, a cholangiocarcinoma treatment drug approved for marketing in Macau, China
Press Release: Innovent Announces the Appointment of Dr. Nageatte Ibrahim as the Oncology Chief Medical Officer (CMO)
Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of cancer, metabolic, autoimmune and other major diseases, today announces the appointment of Dr. Nageatte Ibrahim
No Data